Brokers Issue Forecasts for Chemed Corp.’s Q3 2017 Earnings (CHE)
Chemed Corp. (NYSE:CHE) – Equities researchers at KeyCorp issued their Q3 2017 earnings per share (EPS) estimates for shares of Chemed Corp. in a note issued to investors on Monday. KeyCorp analyst J. Gurda anticipates that the company will earn $2.02 per share for the quarter. KeyCorp currently has a “Sector Weight” rating on the stock. KeyCorp also issued estimates for Chemed Corp.’s Q4 2017 earnings at $2.24 EPS, FY2017 earnings at $8.00 EPS, FY2018 earnings at $9.10 EPS and FY2019 earnings at $9.78 EPS.
A number of other research analysts also recently weighed in on CHE. BidaskClub downgraded Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Royal Bank Of Canada reiterated a “hold” rating and set a $208.00 price target on shares of Chemed Corp. in a report on Wednesday, July 5th. TheStreet downgraded Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. lifted their price target on Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target on the stock in a report on Friday, July 28th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Chemed Corp. presently has a consensus rating of “Hold” and a consensus price target of $214.00.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/brokers-issue-forecasts-for-chemed-corp-s-q3-2017-earnings-che/1537281.html.
Shares of Chemed Corp. (CHE) opened at 197.38 on Thursday. The firm has a market capitalization of $3.16 billion, a price-to-earnings ratio of 48.97 and a beta of 1.14. Chemed Corp. has a 52 week low of $132.92 and a 52 week high of $216.01. The firm has a 50-day moving average price of $196.29 and a 200-day moving average price of $194.53.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm had revenue of $415.06 million for the quarter, compared to analyst estimates of $407.56 million. During the same period last year, the company earned $1.80 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares during the period. Vanguard Group Inc. increased its stake in Chemed Corp. by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock valued at $374,435,000 after buying an additional 34,938 shares during the period. Neuberger Berman Group LLC increased its stake in Chemed Corp. by 2.2% in the first quarter. Neuberger Berman Group LLC now owns 1,060,403 shares of the company’s stock valued at $193,725,000 after buying an additional 23,306 shares during the period. Acadian Asset Management LLC increased its stake in Chemed Corp. by 1.3% in the second quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock valued at $118,454,000 after buying an additional 7,636 shares during the period. Finally, Van Berkom & Associates Inc. increased its stake in Chemed Corp. by 0.5% in the first quarter. Van Berkom & Associates Inc. now owns 467,536 shares of the company’s stock valued at $85,414,000 after buying an additional 2,260 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.
In other Chemed Corp. news, insider Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the transaction, the insider now owns 37,809 shares in the company, valued at $7,465,765.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the transaction, the insider now owns 173,801 shares in the company, valued at approximately $34,961,809.16. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.
The company also recently announced a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Monday, August 14th were paid a $0.28 dividend. The ex-dividend date was Thursday, August 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.57%. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. Chemed Corp.’s payout ratio is 28.07%.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.